Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 401-414 , June 2007

Targeting Myocardial β-Adrenergic Receptor Signaling and Calcium Cycling for Heart Failure Gene Therapy

  • Sven T. Pleger, MD
    • ,
  • Matthieu Boucher, PhD
    • ,
  • Patrick Most, MD
    • ,
  • Walter J. Koch, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Walter J. Koch, PhD, W.W. Smith Professor of Medicine, Director, Center for Translational Medicine, Jefferson Medical College, Thomas Jefferson University, 1025 Walnut Street, 3rd Floor, Philadelphia, PA, 19107.

Received 1 August 2006 ,Revised 9 January 2007 ,Accepted 11 January 2007.

References 

  1. American Heart Association. Heart disease and stroke statistics. Available from: www.americanheart.org/presenter.jhtml?presenter=2007. Accessed April 30, 2007.
  2. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–350
  3. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997;45:968–974
  4. del Monte F, Hajjar R. Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol. 2003;546:49–61
  5. Williams ML, Koch WJ. Viral-based myocardial gene therapy approaches to alter cardiac function. Annu Rev Physiol. 2004;66:49–75
  6. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: β-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005;2:475–483
  7. Keys JR, Koch WJ. The adrenergic pathway and heart failure. Recent Prog Horm Res. 2004;59:13–30
  8. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002;34:951–969
  9. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198–205
  10. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51:651–690
  11. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ. Model systems for the study of seven-transmembrane-segment receptors. Ann Rev Biochem. 1991;60:653–688
  12. Hartzell HC. Regulation of cardiac ion channels by catecholamines, acetylcholine and second messenger systems. Prog Biophys Mol Biol. 1988;52:165–247
  13. Clapham DE, Neer EJ. G protein βγ subunits. Annu Rev Pharmacol Toxicol. 1997;37:167–203
  14. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206–212
  15. Steinberg S. β2-adrenergic receptor signaling complexes in cardiomyocyte caveolae/lipid rafts. J Mol Cell Cardiol. 2004;37:407–415
  16. Xiao RP, Zhu W, Zheng M, Chakir K, Bond R, Lakatta EG, et al. Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci. 2004;25:358–365
  17. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocytes apoptosis. Role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210–2212
  18. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A. 2001;98:1607–1612
  19. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J. 1990;4:2881–2889
  20. Inglese J, Freedman NJ, Koch WJ, Lefkowitz RJ. Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem. 1993;268:23735–23738
  21. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3:639–650
  22. Claing A, Laporte S, Caron MG, Lefkowitz RJ. Endocytosis of G protein-coupled receptors: Roles of G protein-coupled receptor kinases and β-arrestin proteins. Prog Neurobiol. 2002;66:61–79
  23. Penn RB, Pronin AN, Benovic JL. Regulation of G protein-coupled receptor kinases. Trends Cardiovasc Med. 2000;10:81–89
  24. Koch WJ, Inglese J, Stone WC, Lefkowitz RJ. The binding site for the bg subunits of heterotrimeric G proteins on the β-adrenergic receptor kinase. J Biol Chem. 1993;268:8256–8260
  25. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, et al. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor. Science. 1995;268:1350–1353
  26. Akhter SA, Eckhart AD, Rockman HA, Shotwell K, Lefkowitz RJ, Koch WJ. In vivo inhibition of elevated myocardial β-adrenergic receptor kinase in hybrid transgenic mice restores normal β-adrenergic signaling and function. Circulation. 1999;100:648–653
  27. White DC, Hata JA, Shah AS, Glower DD, Lefkowitz R, Koch WJ. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A. 2000;97:5428–5433
  28. Jaber M, Koch WJ, Rockman HA, Smith B, Bond RA, Sulik K, et al. Essential role of β-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci U S A. 1996;93:12974–12979
  29. Rockman HA, Choi DJ, Akhter SA, Jaber M, Giros B, Lefkowitz RJ, et al. Regulation of myocardial contractile function by the level of β-adrenergic receptor kinase-1 in gene targeted mice. J Biol Chem. 1998;273:18180–18184
  30. Bristow MR, Ginsburg R, Minobe W, Cubicciotti R, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. New Engl J Med. 1982;307:205–211
  31. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, et al. Reduced β1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993;92:2737–2745
  32. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation. 1993;87:454–463
  33. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300–1305
  34. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, et al. The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534–1539
  35. Petrofski JA, Koch WJ. The β-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol. 2003;35:1167–1174
  36. Dzimiri N, Basco C, Moorji A, Afrane B, Al-Halees Z. Characterization of lymphocyte β2-adrenoceptor signaling in patients with left ventricular volume overload disease. Clin Exp Pharmacol Physiol. 2002;29:181–188
  37. Dzimiri N, Muiya P, Andres E, Al-Halees Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur J Pharmacol. 2004;489:167–177
  38. Harris CA, Chuang TT, Scorer CA. Expression of GRK2 is increased in the left ventricles of cardiomyopathic hamsters. Basic Res Cardiol. 2001;96:364–368
  39. Cho MC, Rao M, Koch WJ, Thomas SA, Palmiter RD, Rockman HA. Enhanced contractility and decreased β-adrenergic receptor kinase-1 in mice lacking endogenous norepinephrine and epinephrine. Circulation. 1999;99:2702–2707
  40. Anderson KM, Eckhart AD, Willette RN, Koch WJ. The myocardial β-adrenergic system in spontaneously hypertensive herat failure (SHHF) rats. Hypertension. 1999;33:402–407
  41. Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ, Ross J, et al. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A. 1998;95:7000–7005
  42. Yi XP, Gerdes AM, Li F. Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats. Hypertension. 2002;39:1058–1063
  43. Vinge LE, Oie E, Andersson Y, Grogaard HK, Andersen G, Attramadal H. Myocardial distribution and regulation of GRK and β-arrestin isoforms in congestive heart failure in rats. Am J Physiol Heart Circ Physiol. 2001;281:H2490–H2499
  44. Ping P, Anzai T, Gao M, Hammond HK. Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol Heart Circ Physiol. 1997;273:H707–H717
  45. Ungerer M, Kessebohm K, Kronsbein K, Lohse MJ, Richardt G. Activation of β-adrenergic receptor kinase during myocardial ischemia. Circ Res. 1996;79:455–460
  46. Choi DJ, Koch WJ, Hunter JJ, Rockman HA. Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase. J Biol Chem. 1997;272:17223–17229
  47. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest. 1997;99:2087–2093
  48. Iaccarino G, Keys JR, Rapacciuolo A, Shotwell KF, Lefkowitz RJ, Rockman HA, et al. Regulation of myocardial βARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing α1B-adrenergic receptors. J Am Coll Cardiol. 2001;38:534–540
  49. Sigurdsson A. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. 1. Blood Press; 1995;1–45
  50. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169–175
  51. Iaccarino G, Dolber PC, Lefkowitz RJ, Koch WJ. β-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by β- but not α1-adrenergic stimulation. Hypertension. 1999;33:396–401
  52. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor expression by β-adrenergic receptor stimulation and blockade. Circulation. 1998;98:1783–1789
  53. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823
  54. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray?. J Am Coll Cardiol. 1993;22:119A–126A
  55. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. N Engl J Med. 2001;345:1435–1443
  56. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316–2322
  57. Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores β-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation. 2001;104:881–886
  58. Hata JA, Williams ML, Schroder JN, Lima B, Keys JR, Blaxall BC, et al. Lymphocyte levels of GRK2 (βARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved β-adrenergic signaling after mechanical unloading. J Card Fail. 2006;12:360–368
  59. Iaccarino G, Barbato E, Cipolletta E, De Amicis V, Margulies KB, Leosco D, et al. Elevated myocardial and lymphocyte GRK2 expression in human heart failure. Eur Heart J. 2005;26:1752–1758
  60. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specific regulation of the α-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991;266:24613–24620
  61. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, et al. Myocardial-directed overexpression of the human β1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817–830
  62. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059–7064
  63. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, et al. Enhanced myocardial function in transgenic mice overexpressing the β2-adrenergic receptor. Science. 1994;264:582–586
  64. Kohout TA, Takaoka H, McDonald PH, Perry SJ, Mao L, Lefkowitz RJ, et al. Augmentation of cardiac contractility mediated by the human β3-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation. 2001;104:2485–2491
  65. Iaccarino G, Rockman HA, Shotwell KF, Tomhave ED, Koch WJ. Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Am J Physiol Heart Circ Physiol. 1998;275:H1298–H1306
  66. Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci U S A. 1996;93:9954–9959
  67. Hata JA, William ML, Koch WJ. Genetic manipulation of myocardial β-adrenergic receptor activation and desensitization. J Mol Cell Cardiol. 2004;37:11–21
  68. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, et al. Early and delayed consequences of β2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101:1707–1714
  69. Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, Eschenhagen T, et al. Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res. 1999;84:43–52
  70. Gong H, Adamson DL, Ranu HK, Koch WJ, Heubach JF, Ravens U, et al. The effect of Gi-protein inactivation on basal, and β1- and β2AR-stimulated contraction of myocytes from transgenic mice overexpressing the β2-adrenoceptor. Br J Pharmacol. 2000;131:594–600
  71. Belevych AE, Juranek I, Harvey RD. Protein kinase C regulates functional coupling of β1-adrenergic receptors to Gi/o-mediated responses in cardiac myocytes. FASEB J. 2004;18:367–369
  72. Akhter SA, Skaer CA, Kypson AP, McDonald PH, Peppel KC, Glower DD, et al. Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A. 1997;94:12100–12105
  73. Drazner MH, Peppel KC, Dyer S, Grant AO, Koch WJ, Lefkowitz RJ. Potentiation of β-adrenergic signaling by adenoviral-mediated gene transfer in adult rabbit ventricular myocytes. J Clin Invest. 1997;99:288–296
  74. Maurice JP, Hata JA, Shah AS, White DC, McDonald PH, Dolber PC, et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary β2-adrenergic receptor gene delivery. J Clin Invest. 1999;104:21–29
  75. Shah AS, Lilly RE, Kypson AP, Tai O, Hata JA, Pippen A, et al. Intracoronary adenovirus-mediated delivery and overexpression of the β2-adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation. 2000;101:408–414
  76. Kawahira Y, Sawa Y, Nishimura M, Sakakida S, Ueda H, Kaneda Y, et al. In vivo transfer of a β2-adrenergic receptor gene into the pressure-overloaded rat heart enhances cardiac response to β-adrenergic agonist. Circulation. 1998;98:II262–II267
  77. Kypson A, Hendrickson S, Akhter S, Wilson K, McDonald P, Lilly R, et al. Adenovirus-mediated gene transfer of the β2-adrenergic receptor to donor hearts enhances cardiac function. Gene Ther. 1999;6:1298–1304
  78. Tevaearai HT, Eckhart AD, Walton GB, Keys JR, Wilson K, Koch WJ. Myocardial gene transfer and overexpression of β2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation. 2002;106:124–129
  79. Hon JK, Yacoub MH. Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg. 2003;75:S36–S41
  80. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355:1873–1884
  81. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A. 2001;98:5809–5814
  82. Cho MC, Rapacciuolo A, Koch WJ, Kobayashi Y, Jones LR, Rockman HA. Defective β-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem. 1999;274:22251–22256
  83. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001;107:967–974
  84. Eckhart AD, Koch WJ. Expression of a β-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes. Mol Ther. 2002;5:74–79
  85. Williams ML, Hata JA, Schroder J, Rampersaud E, Petrofski J, Jakoi A, et al. Targeted β-adrenergic receptor kinase (βARK1) inhibition by gene transfer in failing human hearts. Circulation. 2004;109:1590–1593
  86. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, et al. In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001;103:1311–1316
  87. Emani SM, Shah AS, Bowman MK, Emani S, Wilson K, Glower DD, et al. Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow-rate. Mol Ther. 2003;8:306–313
  88. Parsa CJ, Reed RC, Walton GB, Pascal LS, Thompson RB, Petrofski JA, et al. Catheter-mediated subselective intracoronary gene delivery to the rabbit heart: introduction of a novel method. J Gene Med. 2005;7:595–603
  89. Emani SM, Shah AS, White DC, Glower DD, Koch WJ. Right ventricular gene therapy with a β-adrenergic receptor kinase inhibitor improves survival after pulmonary artery banding. Ann Thor Surg. 2001;72:1657–1661
  90. Emani SM, Shah AS, Bowman MK, White DC, Emani S, Glower DD, et al. Right ventricular targeted gene transfer of a β-adrenergic receptor kinase inhibitor improves ventricular performance after pulmonary artery banding. J Thorac Cardiovasc Surg. 2004;127:787–793
  91. Tevaearai HT, Eckhart AD, Shotwell KF, Wilson K, Koch WJ. Ventricular dysfunction after cardioplegic arrest is improved after myocardial gene transfer of a β-adrenergic receptor kinase inhibitor. Circulation. 2001;104:2069–2074
  92. Tevaearai HT, Walton GB, Keys JR, Koch WJ, Eckhart AD. Acute ischemic cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the β-adrenergic receptor kinase (βARK1). J Gene Med. 2005;7:1172–1177
  93. Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP, Kudej RK, et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsα overexpression. Circ Res. 1996;78:517–524
  94. Geng YJ, Ishikawa Y, Vatner DE, Wagner TE, Bishop SP, Vatner SF, et al. Apoptosis of cardiac myocytes in Gsα transgenic mice. Circ Res. 1999;84:34–42
  95. Gao MH, Lai NV, Roth DM, Zhou J, Zhu J, Anzai T, et al. Adenylyl cyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation. 1999;99:1618–1622
  96. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94:8121–8126
  97. Roth DM, Gao MH, Lai NC, Drumm J, Dalton N, Zhou JY, et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation. 1999;99:3099–3102
  98. Roth DM, Bayat H, Drumm JD, Gao MH, Swaney JS, Ander A, et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation. 2002;105:1989–1994
  99. Lai NC, Roth DM, Gao MH, Fine S, Head BP, Zhu J, et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation. 2000;102:2396–2401
  100. Lai NC, Roth DM, Gao MH, Tang T, Dalton N, Lai YY, et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation. 2004;110:330–336
  101. Dash B, Kadambi VJ, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, et al. Interactions between phospholamban and β-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation. 2001;103:889–896
  102. Kiriazis H, Kranias EG. Geneticaly engineered models with alterations in cardiac membrane calcium-handling proteins. Annu Rev Physiol. 2000;62:321–351
  103. Houser SR, Piacentino V, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol. 2000;32:1595–1607
  104. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP126 from the calcium release channel (ryanodine receptor): effective regulation in failing hearts. Cell. 2000;101:365–376
  105. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004;94:e61–e70
  106. Saraiva RM, Hare JM. Nitric oxide signaling in the cardiovascular system: implications for heart failure. Curr Opin Cardiol. 2006;21:221–228
  107. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science. 1998;279:234–237
  108. Kaplan P, Babusikova E, Lehotsky J, Dobrota D. Free radical-induced protein modification and inhibition of Ca2+-ATPase of cardiac sarcoplasmic reticulum. Mol Cell Biochem. 2003;248:41–47
  109. Weber CR, Piacentino V, Houser SR, Bers DM. Dynamic regulation of sodium/calcium exchange function in human heart failure. Circulation. 2003;108:2224–2229
  110. Bassani RA, Bers DM. Rate of diastolic Ca2+ release from the sarcoplasmic reticulum of intact rabbit and rat ventricular myocytes. Biophys J. 1995;68:2015–2022
  111. Kaprielian R, del Monte F, Hajjar RJ. Targeting Ca2+ cycling proteins and the action potential in heart failure by gene transfer. Basic Res Cardiol. 2002;97:I136–I145
  112. Pogwizd SM, Bers DM. Na/Ca exchange in heart failure: contractile dysfunction and arrhythmogenesis. Ann NY Acad Sci. 2002;976:454–465
  113. Bers DM, Pogwizd SM, Schlotthauer K. Upregulated Na/Ca exchange is involved in both contractile dysfunction and arrhythmogenesis in heart failure. Basic Res Cardiol. 2002;97:I36–I42
  114. Haghighi K, Gregory KN, Kranias EG. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun. 2004;322:1214–1222
  115. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta. 1999;1450:191–231
  116. Maco B, Mandinova A, Durrenberger MB, Schafer BW, Uhrik B, Heizmann CW. Ultrastructual distribution of the S100A1 Ca2+-binding protein in the human heart. Physiol Res. 2001;50:567–574
  117. Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regu Integr Comp Physiol 2007 Apr 25 [Epub ahead of print] doi:10.1152/ajpregu.00075.2007.
  118. Remppis A, Greten T, Schafer BW, Hunziker P, Erne P, Katus HA, et al. Altered expression of the Ca2+-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta. 1996;1313:253–257
  119. Most P, Boerries M, Eicher C, Schweda C, Volkers M, Wedel T, et al. Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci. 2005;118:421–431
  120. Remppis A, Pleger ST, Most P, Lindenkamp J, Ehlermann P, Schweda C, et al. Genetic modification of engineered heart tissue (EHT): S100A1 gene transfer strengthens EHT. J Gene Med. 2004;6:387–394
  121. Remppis A, Most P, Löffler E, Ehlermann P, Bernotat J, Pleger S, et al. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol. 2002;97:I56–I62
  122. Most P, Ehlermann P, Bernotat J, Pleger ST, Borries M, Reppel M, et al. S100A1: A novel regulator of myocardial contractility. Proc Natl Acad Sci U S A. 2001;98:13889–13894
  123. Kettlewell S, Most P, Currie S, Koch WJ, Smith GL. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol. 2005;39:900–910
  124. Most P, Pleger ST, Volkers M, Heidt B, Boerries M, Weichenhan D, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004;114:1550–1563
  125. Völkers M, Loughrey CM, MacQuaide N, Rempiss A, deGeorge B, v. Wegner F, et al. S100A1 decreases calcium spark frequency and alters their characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium. 2007;41:135–143
  126. Usui A, Kato K, Sasa H, Minaguchi K, Abe T, Murase M, et al. S-100a. protein in serum during acute myocardial infarction. Clin Chem. 1990;36:639–641
  127. Okada M, Hatakeyama T, Itoh H, Tokuta N, Tokumitsu H, Kobayashi R. S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90 multichaperone complex. J Biol Chem. 2004;279:4221–4233
  128. Most P, Boerries M, Eicher C, Schweda C, Ehlermann P, Pleger ST, et al. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem. 2003;278:48404–48412
  129. Most P, Remppis A, Pleger ST, Loffler E, Ehlermann P, Bernotat J, et al. Transgenic overexpression of the Ca2+ binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem. 2003;278:33809–33817
  130. Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, et al. Cardiac S100A1 protein levels determine contractile performance and propensity towards heart failure after myocardial infarction. Circulation. 2006;114:1258–1268
  131. Zhukova L, Zhukov I, Bal W, Wyslouch-Cieszynska A. Redox modifications of the C-terminal cysteine residue cause structural changes in S100A1 and S100B proteins. Biochim Biophys Acta. 2004;1742:191–201
  132. Pleger ST, Remppis A, Heidt B, Volkers M, Chuprun JK, Kuhn M, et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther. 2005;12:1120–1129
  133. Tsoporis JN, Marks A, Zimmer DB, McMahon C, Parker TG. The myocardial protein S100A1 plays a role in the maintenance of normal gene expression in the adult heart. Mol Cell Biochem. 2003;242:27–33
  134. Du XJ, Cole TJ, Tenis N, Gao XM, Kontgen F, Kemp BE, et al. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biochem. 2002;22:2821–2829
  135. Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch WJ, et al. The Ca2+-dependent interaction of S100A1 with the F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol 2007; Apr 16 [Epub ahead of print] doi:10.1128/MCB.02045-06.
  136. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007;115:2506–2515

 The work of S.T.P. is supported by an American Heart Association postdoctoral fellow award. M.B. is supported by an American Heart Association postdoctoral fellow award and a Fonds de la Recherche en Santé du Québec postdoctoral scholarship. P.M. is supported by the Deutsche Forschungsgemeinschaft (MO 1066/1-1) and the Bundesministerium fuer Bildung und Forschung (01GU0527). W.J.K. is a Fellow of the American Heart Association (FAHA) and is supported by National Institute of Health R01 grants HL61690, HL56205 and P01-HL075443 (Project 2).S.T.P. and M.B. contributed equally to this article.

PII: S1071-9164(07)00004-8

doi: 10.1016/j.cardfail.2007.01.003

Journal of Cardiac Failure
Volume 13, Issue 5 , Pages 401-414 , June 2007

Article Tools

* Image Usage & Resolution